<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134339</url>
  </required_header>
  <id_info>
    <org_study_id>1609018390</org_study_id>
    <nct_id>NCT03134339</nct_id>
  </id_info>
  <brief_title>The Effect of Nicotine Delivery Rate on Reinforcement</brief_title>
  <official_title>The Effect of Nicotine Delivery Rate on Reinforcement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project
      addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence
      threshold among youth and adults and impact of nicotine reduction on tobacco product use
      behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and
      relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is
      necessary for accurately assessing dose-response and threshold effects. The estimated
      threshold for reinforcement will establish a benchmark for evaluating the addictive potential
      of ECs and other inhaled nicotine products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo-controlled study that will recruit male and female nicotine dependent smokers/EC
      users (n=18) to complete four separate experimental sessions. Each session will include one
      randomly assigned infusion that will be either saline or a single dose of nicotine (1 mg per
      70 kg body weight) delivered at three different infusion rates, rapid, moderate or slow
      (0.24, 0.048 or 0.024 mcg per kg body weight per second). A total infusion duration of 10 min
      will be maintained during each session by adding saline infusions of variable duration after
      nicotine delivery. This will be achieved by two separate infusion pumps, one for saline and
      one for nicotine. For example, the rapid 0.24 mcg/kg/s condition will include a 1 min
      infusion of nicotine followed by a 9 min infusion of saline. The subjects will be blinded to
      the infusion pump procedures. The rapid delivery rate, which we have used in our prior
      studies, induces positive subjective drug effects and suppresses symptoms of nicotine
      withdrawal. The moderate delivery rate,0.048 mcg/kg/s, approximates the rate of nicotine
      intake encountered while smoking a typical cigarette over 5 min (4). The slowest nicotine
      delivery rate, 0.024mcg/kg/s, was chosen to approximate the rate of nicotine intake
      encountered while using a newer EC (5).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The effects of different IV nicotine delivery rates of (saline), 0.24, 0.048 and 0.024 mcg/kg/s), as a within-subject factor, on peak change in the intensity of subjective effects as measured by the DEQ, will be used as a measured of a reinforcing threshold.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participant and Investigator will not know nicotine dose or rate of infusion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Change on items of the Drug Effects Questionnaire (DEQ)</measure>
    <time_frame>up to 60 minutes post infusion</time_frame>
    <description>The peak change in the intensity of subjective effects as measured by the DEQ</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Nicotine</condition>
  <arm_group>
    <arm_group_label>saline 0.00mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.00 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.24mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.24 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.048mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.048 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.024 mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.024 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine saline 0.00mcg/kg/s</intervention_name>
    <description>saline 0.00mcg/kg/s</description>
    <arm_group_label>saline 0.00mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 0.24 mcg/kg/s</intervention_name>
    <description>nicotine 0.24 mcg/kg/s</description>
    <arm_group_label>0.24mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 0.048 mcg/kg/s</intervention_name>
    <description>nicotine 0.048 mcg/kg/s</description>
    <arm_group_label>0.048mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 0.024 mcg/kg/s</intervention_name>
    <description>nicotine 0.024 mcg/kg/s</description>
    <arm_group_label>0.024 mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male smokers that smoke â‰¥ 5 cigarettes per day for the past year

          2. aged 18 to 30 years

          3. urine cotinine levels &gt; 100 ng/mL consistent with nicotine intake of an active smoker
             (23)

          4. not seeking treatment at the time of the study for nicotine dependence

          5. in good health as verified by medical history, screening examination, and screening
             laboratory tests

          6. for women, not pregnant as determined by pregnancy screening, nor breast feeding, and
             using acceptable birth control methods.

        Exclusion Criteria:

          1. history of major medical or psychiatric disorders that the physician investigator
             deems as contraindicated for the subject to be in the study

          2. regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics)

          3. current alcohol or substance dependence for any other recreational or prescription
             drugs other than nicotine

          4. urine drug screening indicating recent illicit drugs use (with the exception of
             marijuana).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Jensen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lance Barnes</last_name>
    <phone>203-937-4823</phone>
    <email>lance.barnes@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
      <phone>203-937-4809</phone>
      <email>mehmet.sofuoglu@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Jensen, Ph.D.</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4809</phone_ext>
      <email>kevin.jensen@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Jensen, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>The effect of nicotine delivery rate on reinforcement</investigator_title>
  </responsible_party>
  <keyword>nicotine, smoking</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

